Skip to Main Content

++

INTRODUCTION

++

rabeprazole (ra-bep-ra-zole)

Aciphex, Image not available.Pariet

Classification

Therapeutic: antiulcer agents

Pharmacologic: proton-pump inhibitors

++
Indications
++

Gastroesophageal reflux disease (GERD). Duodenal ulcers (including combination therapy with clarithromycin and amoxicillin to eradicate Helicobacter pylori and prevent recurrence). Pathologic hypersecretory conditions, including Zollinger-Ellison syndrome.

++
Action
++

Binds to an enzyme in the presence of acidic gastric pH, preventing the final transport of hydrogen ions into the gastric lumen. Therapeutic Effects: Diminished accumulation of acid in the gastric lumen, with lessened acid reflux. Healing of duodenal ulcers and esophagitis. ↓ acid secretion in hypersecretory conditions.

++
Adverse Reactions/Side Effects
++

CNS: dizziness, headache, malaise. GI: abdominal pain, constipation, diarrhea, nausea. Derm: photosensitivity, rash. MS: neck pain. Misc: allergic reactions, chills, fever.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor improvements in GI symptoms (gastritis, heartburn, and so forth) to help determine if drug therapy is successful.

  • Monitor signs of allergic reactions, including pulmonary symptoms (tightness in the throat and chest, wheezing, cough, dyspnea) or skin reactions (rash, pruritus, urticaria). Notify physician immediately if these reactions occur.

  • Assess dizziness that might affect gait, balance, and other functional activities (See Appendix C). Report balance problems and functional limitations to the physician, and caution the patient and family/caregivers to guard against falls and trauma.

  • Monitor any neck pain to rule out musculoskeletal pathology; that is, attempt to determine if pain is drug induced rather than caused by anatomic or biomechanical problems.

++
Interventions
++

  • In cases of NSAID-induced gastritis, implement appropriate manual therapy techniques, physical agents, and therapeutic exercises to reduce pain and decrease the need for aspirin and other NSAIDs.

  • Causes photosensitivity; use care if administering UV treatments. Advise patient to avoid direct sunlight and use sunscreens and protective clothing.

++
Patient/Client-Related Instruction
++

  • Advise patient to avoid alcohol and foods that may cause an increase in GI irritation.

  • Instruct patient to report bothersome or prolonged side effects, including headache, chills, fever, malaise, or GI effects (nausea, diarrhea, constipation, abdominal pain).

++
Pharmacokinetics
++

Absorption: Delayed-release tablet is designed to allow rabeprazole, which is not stable in gastric acid, to pass through the stomach intact. Subsequently 52% is absorbed after oral administration.

++

Distribution: Unknown.

++

Protein Binding: 96.3%.

++

Metabolism and Excretion: Mostly metabolized by the liver (hepatic cytochrome P450 3A and 2C19 enzyme systems); 10% excreted in feces; remainder excreted in urine as inactive metabolites.

++

Half-life: 1–2 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (acid suppression)

ROUTE ONSET PEAK DURATION
PO within 1 hr unknown 24 hr*

*Suppression continues to increase over the 1st week of therapy.

++
Contraindications/Precautions
...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.